Sanofi’s $15,000-a-Year Heart Drug May Trigger New Cost Concerns
Is a Price War Coming for Cholesterol Drugs?
This article is for subscribers only.
Sanofi and Regeneron Pharmaceuticals Inc. won U.S. approval for a powerful cholesterol-lowering drug that will sell for almost $15,000 a year, likely escalating a nationwide debate over the cost of medicine.
The drug will be sold using the name Praluent. It’s approved for people with a genetic disease causing ultra-high levels of bad cholesterol, and for those with atherosclerotic cardiovascular disease such as heart attacks or strokes, the Food and Drug Administration said in a statement Friday.